These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 5111305)

  • 1. In vitro susceptibility of atypical mycobacteria to rifampin.
    Molavi A; Weinstein L
    Appl Microbiol; 1971 Jul; 22(1):23-5. PubMed ID: 5111305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of mycobacteria to rifampin.
    Woodley CL; Kilburn JO; David HL; Silcox VA
    Antimicrob Agents Chemother; 1972 Oct; 2(4):245-9. PubMed ID: 4670494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effect of rifampin on mycobacteria.
    Lorian V; Finland M
    Appl Microbiol; 1969 Feb; 17(2):202-7. PubMed ID: 4975656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of opportunist mycobacteria to rifampicin and ethambutol.
    Yates MD; Collins CH
    Tubercle; 1981 Jun; 62(2):117-21. PubMed ID: 7303160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs?
    Rastogi N; Goh KS; Guillou N; Labrousse V
    Zentralbl Bakteriol; 1992 Dec; 277(4):474-84. PubMed ID: 1303690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
    Tsukamura M; Yamori S
    Kekkaku; 1990 May; 65(5):349-57. PubMed ID: 2168003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to rifampicin by Mycobacterium kansasii.
    Davidson PT; Waggoner R
    Tubercle; 1976 Dec; 57(4):271-3. PubMed ID: 1014109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination of gentamycin and amikacin with rifampicin, ethambutol and isoniazid on selected standard strains of Mycobacterium species in experiments done in vitro and in vivo].
    Janowiec M; Andrzejczyk Z; Marczewska J
    Pneumonol Pol; 1989 May; 57(5):300-7. PubMed ID: 2633149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of in vitro susceptibility of mycobacteria to ansamycin.
    Heifets LB; Iseman MD
    Am Rev Respir Dis; 1985 Sep; 132(3):710-1. PubMed ID: 3929660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of rifampin-resistance in pathogenic mycobacteria.
    Williams DL; Waguespack C; Eisenach K; Crawford JT; Portaels F; Salfinger M; Nolan CM; Abe C; Sticht-Groh V; Gillis TP
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2380-6. PubMed ID: 7840574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008.
    Wang HX; Yue J; Han M; Yang JH; Gao RL; Jing LJ; Yang SS; Zhao YL
    Chin Med J (Engl); 2010 Jan; 123(2):184-7. PubMed ID: 20137367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differentiation of mycobacteria by the Jones-Mote reaction (author's transl)].
    Kazda I
    Zentralbl Bakteriol Orig A; 1977 Feb; 237(1):90-5. PubMed ID: 842181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimycobacterial activity of rifampin under in vitro and simulated in vivo conditions.
    Stottmeier KD; Kubica GP; Woodley CL
    Appl Microbiol; 1969 Jun; 17(6):861-5. PubMed ID: 4978926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria.
    Wallace RJ; Wiss K; Bushby MB; Hollowell DC
    Rev Infect Dis; 1982; 4(2):326-31. PubMed ID: 7111959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sulfadimethoxine as a promising drug in the treatment of infections caused by Mycobacterium kansasii and Mycobacterium xenopi--differentiation between M. kansasii and M. marinum and between M. gordonae and M. scrofulaceum by the susceptibility testing to sulfadimethoxine].
    Tsukamura M
    Kekkaku; 1989 Apr; 64(4):313-7. PubMed ID: 2747117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
    Woodley CL; Kilburn JO
    Am Rev Respir Dis; 1982 Sep; 126(3):586-7. PubMed ID: 6289711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of Runyon Group I Mycobacteria to rifampicin.
    Saito H; Yamamoto S; Yamura T
    Hiroshima J Med Sci; 1972 Mar; 21(1):35-40. PubMed ID: 4661749
    [No Abstract]   [Full Text] [Related]  

  • 18. In-vitro susceptibility of mycobacteria to ciprofloxacin.
    Collins CH; Uttley AH
    J Antimicrob Chemother; 1985 Nov; 16(5):575-80. PubMed ID: 2934361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activity of alkaline glutaraldehyde solution against a number of atypical mycobacterial species.
    Collins FM
    J Appl Bacteriol; 1986 Sep; 61(3):247-51. PubMed ID: 3096931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.